Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec and UCB have agreed to jointly identify small modulators of priority biological targets for CNS disorders, under a three year integrated drug discovery partnership.
Subscribe to our email newsletter
Under the pact, Evotec will use its drug discovery technologies for identifying small molecules against the UCB selected targets.
The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.
As per the terms of the agreement, UCB is responsible to pay fixed research funding fee as well as discovery, preclinical and clinical milestones to Evotec.
Additonally, UCB will also pay royalties to Evotec based on net sales of any approved drugs under the collaboration.
Further financial details have not been disclosed.